
R R Biotec India Private Limited
Manufacturer and trader of human pharma, veterinary products, and surgical products. Also provides storage facilities.
Manufacturer and trader of human pharma, veterinary products, and surgical products. Also provides storage facilities.
R R Biotec India Private Limited (RRBIPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 December 2014 and has a history of Ten years and three months. Its registered office is in Kala Amb, Himachal Pradesh, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.18 Cr.
The company currently has active open charges totaling ₹95.72 Cr. The company has closed loans amounting to ₹59.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rakesh Goyal, Ranjna Goyal, Rakshit Goyal, and Two other members serve as directors at the Company.
Kala Amb, Himachal Pradesh, India
+91-XXXXXXXXXX
U74999HP2014PTC000836
000836
Private Limited Indian Non-Government Company
30 Dec 2014
30 Sep 2023
31 Mar 2023
Unlisted
Roc Himachal Pradesh
Name | Designation | Appointment Date | Status |
---|---|---|---|
Rakesh Goyal ![]() | Director | 30-Dec-2014 | Current |
Ranjna Goyal ![]() | Director | 30-Dec-2014 | Current |
Rakshit Goyal ![]() | Additional Director | 06-Apr-2023 | Current |
Parmjeet Mankoo | Additional Director | 09-Mar-2024 | Current |
Dimple Garg ![]() | Additional Director | 23-Jun-2023 | Current |
R R Biotec India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 97.59% decrease. The company also saw a substantial fall in profitability, with a 16.64% decrease in profit. The company's net worth Soared by an impressive increase of 10.15%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations | |||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, R R Biotec India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Rakesh Goyal, Ranjna Goyal and 1 more are mutual person
Rakesh Goyal, Ranjna Goyal and 1 more are mutual person
Rakesh Goyal, Ranjna Goyal and 1 more are mutual person
Rakesh Goyal, Ranjna Goyal and 1 more are mutual person
Rakesh Goyal, Ranjna Goyal and 1 more are mutual person
Rakesh Goyal, Ranjna Goyal and 1 more are mutual person
₹95.72 Cr
₹59.00 Cr
Date | Lender | Amount | Status |
---|---|---|---|
12 Sep 2023 | Others | ₹46.00 Cr | Open |
07 Aug 2023 | Others | ₹5.50 Cr | Open |
07 Aug 2023 | Others | ₹3.80 M | Open |
01 Aug 2023 | Others | ₹43.84 Cr | Open |
25 Apr 2023 | Others | ₹29.50 Cr | Satisfied |
Unlock and access historical data on people associated with R R Biotec India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of R R Biotec India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R R Biotec India's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Parmjeet Singh Mankoo was appointed as a Additional Director was appointed as a Additional Director on 09 Mar 2024 & has been associated with this company since 1 year 1 month .
R R Biotec India Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.
A charge with Others amounted to Rs. 46.00 Cr with Charge ID 100785696 was registered on 12 Sep 2023.
A charge registered on 25 Apr 2023 via Charge ID 100712821 with Others was fully satisfied on 04 Sep 2023.
A charge registered on 25 Apr 2023 via Charge ID 100715700 with Others was fully satisfied on 04 Sep 2023.
A charge with Others amounted to Rs. 5.50 Cr with Charge ID 100772954 was registered on 07 Aug 2023.
R R Biotec India Private Limited was incorporated on 30 Dec 2014.
The authorized share capital of R R Biotec India Private Limited is ₹ 3.00 Cr and paid-up capital is ₹ 2.18 Cr.
Currently 5 directors are associated with R R Biotec India Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of R R Biotec India Private Limited is C/O Orison Pharma International Sadhoura Road, Kala Amb, Himachal Pradesh, India, 173030.
The corporate identification number (CIN) of R R Biotec India Private Limited is U74999HP2014PTC000836 and the company number is 000836 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for R R Biotec India Private Limited has fallen by -97.59%.
The financial reports for the fiscal year 2023 indicates that The net worth of R R Biotec India Private Limited has experienced an upsurge of 10.15%.
As per the financial statements for fiscal Year 2023, The total open charges for R R Biotec India Private Limited amount to ₹ 95.72 Cr.
The most recent Balance Sheet for R R Biotec India Private Limited was filed with the ROC on 31 Mar 2023.
Search company & director profiles for free and gain access to critical business data.